- Home
- BCV vs MCRB Comparison
BCV vs MCRB Comparison
Compare BCV & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCV
- MCRB
- Stock Information
- Founded
- BCV 1971
- MCRB 2010
- Country
- BCV United States
- MCRB United States
- Employees
- BCV N/A
- MCRB N/A
- Industry
- BCV Finance/Investors Services
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- BCV Finance
- MCRB Health Care
- Exchange
- BCV Nasdaq
- MCRB Nasdaq
- Market Cap
- BCV 115.1M
- MCRB 125.7M
- IPO Year
- BCV N/A
- MCRB 2015
- Fundamental
- Price
- BCV $20.13
- MCRB $16.86
- Analyst Decision
- BCV
- MCRB Hold
- Analyst Count
- BCV 0
- MCRB 4
- Target Price
- BCV N/A
- MCRB $73.67
- AVG Volume (30 Days)
- BCV 26.3K
- MCRB 134.5K
- Earning Date
- BCV 01-01-0001
- MCRB 08-06-2025
- Dividend Yield
- BCV 8.13%
- MCRB N/A
- EPS Growth
- BCV N/A
- MCRB N/A
- EPS
- BCV N/A
- MCRB 10.22
- Revenue
- BCV N/A
- MCRB N/A
- Revenue This Year
- BCV N/A
- MCRB N/A
- Revenue Next Year
- BCV N/A
- MCRB N/A
- P/E Ratio
- BCV N/A
- MCRB $1.65
- Revenue Growth
- BCV N/A
- MCRB N/A
- 52 Week Low
- BCV $14.09
- MCRB $6.53
- 52 Week High
- BCV $18.11
- MCRB $26.40
- Technical
- Relative Strength Index (RSI)
- BCV 71.29
- MCRB 65.85
- Support Level
- BCV $19.69
- MCRB $14.06
- Resistance Level
- BCV $19.92
- MCRB $15.84
- Average True Range (ATR)
- BCV 0.19
- MCRB 1.47
- MACD
- BCV -0.01
- MCRB 0.10
- Stochastic Oscillator
- BCV 86.74
- MCRB 87.71
About BCV Bancroft Fund Ltd.
Bancroft Fund Ltd is a diversified closed-end management company. It operates as a closed-ended equity mutual fund. The funds' main objective is to provide income and potential for capital appreciation. With the intent to achieve its objective, the company invests in convertible and equity securities. It invests across different industries such as Computer Software and Services, Energy and Utilities, Health Care among others.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.